Cancer Trials Ireland shared on LinkedIn:
“A new commentary published in the International Journal of Clinical Pharmacy examines whether Ireland is missing an important opportunity to reduce the financial burden of cancer care through greater use of biosimilars.
The paper highlights the potential for biosimilars to improve treatment equity, expand patient access and support a more sustainable approach to medical oncology, without compromising quality, safety or efficacy.
Congratulations to all involved, including Cancer Trials Ireland Clinical Lead Prof Seamus O’Reilly and respected patient advocate, Siobhán Gaynor. The patient voice is essential to this discussion, particularly when considering access to treatment, equity and the wider impact of rising cancer drug costs.”
Title: Biosimilar use in medical oncology in Ireland: a missed opportunity to mitigate financial toxicity?
Authors: Edel Burton, Kate E. Coakley, Siobhán Gaynor, Mei McDonagh, Christopher Palmer, Laura J. Sahm, Séamus O’Reilly on behalf of Biologics Impact on Patient Care and Treatment (Bio ImPAcT) Consortium
Other articles about Cancer Trials Ireland on OncoDaily.